Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Primary result · ACR20 responseResult — go to the resultOdds ratio 3.19 95% CI 2.96–3.44Authors' conclusion
Within this dataset, it is evident that the conclusions concerning our primary objective were significantly influenced by both the amount and characteristics of missing data.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in randomised trials of targeted interventions
- Participants
- 55,422 patients115 trials
- Comparison
- Biologics and targeted agents vs placebo or conventional DMARDs
- Primary endpoint
- ORs for ACR20 response and at least one of the eight core domains of the RA core outcome set (COS), analysed as SMDs
Methodological detailsunivariable meta-regression
- Univariable meta-regression
Primary result
ACR20 response
Odds ratio
3.19
95% CI 2.96–3.44
Experimental interventionsvs Comparators
OR 3.19 (95% CI 2.96–3.44)
As reported in the abstract
Further findings
Number of core outcome set (COS) domains reported
- Median number of COS domains reported
- 6
- Trials reporting only 1 domain
- 18
- Trials reporting all 8 domains
- 17
Trials reporting all eight core domains only
- Improvement in fatigue explains successful ACR20 response the most
Original publication
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set. Ann Rheum Dis. Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →